Response to therapy in rheumatoid arthritis is influenced by immediately prior therapy

Journal of Rheumatology

Volumn 24, Issue 5, 1997, Pages 838-844

  Fries, James F ^a,b   Williams, Catherine A ^a   Singh, Gurkirpal ^a,b   Ramey, Dena R ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Department of Medicine ^*  (United States)

Author keywords

DMARD THERAPY; RHEUMATOID ARTHRITIS; TREATMENT STRATEGIES IN RA

Indexed keywords

ANTIRHEUMATIC AGENT; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISONE;

ADULT; AGED; ARTICLE; CLINICAL PRACTICE; DECISION MAKING; DISABILITY; FEMALE; HUMAN; HYPOTHESIS; MAJOR CLINICAL STUDY; MALE; PAIN PARAMETERS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TREATMENT PLANNING;

EID: 0031006070     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Cash JM, Klippel JH: Second-line drug therapy for rheumatoid arthritis. N Engl J Med 1994;330:1368-75.
2. Paulus HE, Egger MJ, Ward JR, Williams HJ: Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. The Cooperative Systematic Studies of Rheumatic Diseases Group. Arthritis Rheum 1990;33:477-84.
3. Fries JF: Reevaluating the therapeutic approach to rheumatoid arthritis: The "sawtooth" strategy. J Rheumatol 1990;(suppl 17)22:12-5.
4. Wilske KR, Healey LA: Remodeling the pyramid - a concept whose time has come. J Rheumatol 1989;16:565-7.
5. Hawley DJ, Wolfe F: Are the results of controlled clinical trials and observational studies of second line therapy in rheumatoid arthritis valid and generalizable as measures of rheumatoid arthritis outcome - analysis of 122 studies. J Rheumatol 1991;18:1008-14.
6. Wilke WS: Combination therapy for rheumatoid arthritis - new paradigms of treatment. Clin J Med 1993;60:101-2.
7. Pincus T: The paradox of effective therapies but poor long-term outcomes in rheumatoid arthritis. Semin Arthritis Rheum 1992;21:2-15.
8. Ramey DR, Raynauld JP, Fries JF: The Health Assessment Questionnaire 1992: Status and review. Arthritis Care Res 1992;5:119-29.
9. Ramey DR, Fries JF, Singh G: The Health Assessment Questionnaire 1995 - status and review. In: Spilker B, ed. Pharmacoeconomics and Quality of Life in Clinical Trials, 2nd ed. New York: Raven Press, 1996:227-37.
10. Fries JF, Spitz PW, Young DY: The dimensions of health outcomes: The health assessment questionnaire disability and pain scales. J Rheumatol 1982;9:789-93.
11. Fries JF, Spitz PW, Mitchell DM, Roth SH, Wolfe F, Bloch DA: Impact of specific therapy upon rheumatoid arthritis. Arthritis Rheum 1986;29:620-7.
12. Champion GD, Cairns DR, Bieri D, et al: Dose response studies and longterm evaluation of auranofin in rheumatoid arthritis. J Rheumatol 1988;15:28-34.
13. Missler B, Bandilla KK: Longterm results of auranofin therapy. Clin Rheumatol 1987;6:350-42.
14. Pincus T, Marcum SB, Callahan LF: Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone. J Rheumatol 1992;19:1885-90.